Photo by nci from unsplash
Results from the ERA 223 trial of abiraterone combined with radium-223 among men with chemotherapy-naïve castration-resistant prostate cancer and bone metastases show no improvement in survival free from symptomatic skeletal… Click to show full abstract
Results from the ERA 223 trial of abiraterone combined with radium-223 among men with chemotherapy-naïve castration-resistant prostate cancer and bone metastases show no improvement in survival free from symptomatic skeletal events. We hypothesize that this finding might be attributable to bone loss induced by the concomitantly administered prednisone.
Keywords:
combined radium;
radium 223;
prostate cancer;
higher risk;
abiraterone
Journal Title: European urology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: European urology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!